Noesis Capital Mangement Corp Purchases 2,394 Shares of Stryker Corporation $SYK

Noesis Capital Mangement Corp boosted its position in shares of Stryker Corporation (NYSE:SYK) by 3.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 69,303 shares of the medical technology company’s stock after purchasing an additional 2,394 shares during the period. Stryker accounts for approximately 3.5% of Noesis Capital Mangement Corp’s portfolio, making the stock its 6th largest holding. Noesis Capital Mangement Corp’s holdings in Stryker were worth $24,358,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. United Financial Planning Group LLC acquired a new stake in Stryker during the third quarter worth about $27,000. CGC Financial Services LLC acquired a new stake in Stryker during the fourth quarter worth about $29,000. Strive Asset Management LLC acquired a new stake in Stryker during the third quarter worth about $30,000. ANTIPODES PARTNERS Ltd acquired a new stake in Stryker during the third quarter worth about $34,000. Finally, Copia Wealth Management grew its stake in Stryker by 181.6% during the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock worth $40,000 after buying an additional 69 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Up 0.4%

SYK opened at $306.74 on Friday. The company’s 50 day moving average is $329.68 and its 200-day moving average is $351.73. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a market cap of $117.59 billion, a P/E ratio of 35.50, a PEG ratio of 1.93 and a beta of 0.80.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the previous year, the business posted $2.84 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president directly owned 177 shares in the company, valued at $50,170.65. This trade represents a 95.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Wells Fargo & Company reduced their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. BTIG Research reduced their price objective on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Finally, Canaccord Genuity Group reduced their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.